Evidence map›Paper›PMID 39858094›Full record

ReviewCancers2025

A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma.

Qian Qin, Isamu Tachibana, Vitaly Margulis, Jeffrey A Cadeddu, Tian Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qian QinDivision of Hematology and Medical Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX 75235, USA.
Isamu TachibanaDepartment of Urology, University of Texas Southwestern, Dallas, TX 75235, USA.ORCID 0000-0002-0950-1296
Vitaly MargulisDepartment of Urology, University of Texas Southwestern, Dallas, TX 75235, USA.
Jeffrey A CadedduDepartment of Urology, University of Texas Southwestern, Dallas, TX 75235, USA.
Tian ZhangDivision of Hematology and Medical Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX 75235, USA.ORCID 0000-0001-8914-3531

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEGFR-TKI) now set as the standard front-line treatment for advanced renal cell carcinoma (RCC). However, the roles of VEGFR-TKIs and IOs in the neoadjuvant setting for locoregional/locally advanced RCC remain undefined, where the goals may be primary tumor downsizing/downstaging and potentially eradicating micrometastatic disease. This review will examine VEGFR-TKI monotherapy, IO monotherapy, and VEGFR-TKI/IO combination regimens in a preoperative setting with a focus on the efficacy, toxicity, surgical, and long-term implications.

Indexed as

immune checkpoint inhibitorkidney cancerneoadjuvantpre-operativerenal cell carcinomavascular endothelial growth factor receptor-tyrosine kinase inhibitor

Identifiers

PMID39858094
PMCPMC11763366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.